170 related articles for article (PubMed ID: 15226775)
1. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.
Hitchings AW; Kumar M; Jordan S; Nargund V; Martin J; Berney DM
Br J Cancer; 2004 Aug; 91(3):552-7. PubMed ID: 15226775
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers.
Korkolopoulou P; Christodoulou P; Lazaris A; Thomas-Tsagli E; Kapralos P; Papanikolaou A; Kalliteraki I; Davaris P
Eur Urol; 2001 Feb; 39(2):167-77. PubMed ID: 11223676
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
4. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
5. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.
Lee K; Jung ES; Choi YJ; Lee KY; Lee A
J Korean Med Sci; 2010 Oct; 25(10):1449-55. PubMed ID: 20890425
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
7. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
Santos LL; Amaro T; Pereira SA; Lameiras CR; Lopes P; Bento MJ; Oliveira J; Criado B; Lopes CS
Eur J Surg Oncol; 2003 Feb; 29(1):74-80. PubMed ID: 12559081
[TBL] [Abstract][Full Text] [Related]
8. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens.
Tokunaga H; Shariat SF; Green AE; Brown RM; Zhou JH; Benedict WF; Lerner SP
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):16-22. PubMed ID: 11516846
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
10. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
12. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
Dong Y; Walsh MD; McGuckin MA; Cummings MC; Gabrielli BG; Wright GR; Hurst T; Khoo SK; Parsons PG
Int J Cancer; 1997 Aug; 74(4):407-15. PubMed ID: 9291430
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
15. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
17. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
